Mather Group LLC. Takes Position in DaVita Inc. (NYSE:DVA)

Mather Group LLC. bought a new stake in DaVita Inc. (NYSE:DVA) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 857 shares of the company’s stock, valued at approximately $118,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Newbridge Financial Services Group Inc. acquired a new position in shares of DaVita during the fourth quarter worth about $30,000. Hanseatic Management Services Inc. acquired a new position in shares of DaVita during the third quarter worth about $36,000. Principal Securities Inc. acquired a new position in shares of DaVita during the fourth quarter worth about $37,000. GAMMA Investing LLC acquired a new position in shares of DaVita during the fourth quarter worth about $60,000. Finally, Quest Partners LLC acquired a new position in shares of DaVita during the fourth quarter worth about $74,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Trading Up 0.8 %

Shares of DVA opened at $141.38 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.37 and a debt-to-equity ratio of 7.95. The firm’s 50-day moving average is $138.36 and its two-hundred day moving average is $125.37. DaVita Inc. has a twelve month low of $71.51 and a twelve month high of $147.93. The firm has a market capitalization of $12.40 billion, a P/E ratio of 16.07, a PEG ratio of 1.07 and a beta of 0.96.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Thursday, May 2nd. The company reported $2.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.95 by $0.43. DaVita had a net margin of 6.61% and a return on equity of 68.52%. The company had revenue of $3.07 billion for the quarter, compared to the consensus estimate of $3.03 billion. During the same quarter in the prior year, the firm earned $1.58 earnings per share. The company’s revenue for the quarter was up 6.9% compared to the same quarter last year. On average, research analysts predict that DaVita Inc. will post 9.62 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Barclays boosted their price target on shares of DaVita from $133.00 to $150.00 and gave the stock an “equal weight” rating in a research note on Monday, May 6th. StockNews.com lowered shares of DaVita from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 8th. Finally, Truist Financial upped their target price on shares of DaVita from $135.00 to $150.00 and gave the stock a “hold” rating in a research report on Wednesday, May 15th. Two research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $144.67.

Insider Buying and Selling at DaVita

In other DaVita news, Director Barbara J. Desoer sold 5,030 shares of the company’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $138.81, for a total value of $698,214.30. Following the sale, the director now owns 10,954 shares of the company’s stock, valued at $1,520,524.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 2.00% of the company’s stock.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.